Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

In a report released today, Jonathan Wolleben from JMP Securities maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price ...

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris (PHVS – Research Report) today and set a price target of $34.00. The ...

The NOD-like receptor family pyrin domain-containing 3 (NLRP3 ... ultimately inhibiting NLRP3 inflammasome activation (Figure 2). Figure 2. Role of exercise-mediated gut microbiota in inhibiting NLRP3 ...

This study compares immune proteins and bioactive peptides in cow and camel milk, highlighting camel milk's lower allergenic ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half ...

Here we discuss diacylglycerol-mediated insulin resistance as an alternative and unifying hypothesis to explain the most common forms of insulin resistance associated with obesity and type 2 ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

EPFL researchers have developed a computational method to explicitly consider the impact of water while designing membrane ...